Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04927429 · ClinicalTrials.gov registry record

Technical Development of Cardiovascular Magnetic Resonance Imaging

A clinical trial of Cardiovascular Disease, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Recruiting
Registry status
3,400
Enrollment target
2
Study locations

NCT04927429: Recruiting study of Cardiovascular Disease, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

NCT04927429 is a study of Cardiovascular Disease that is actively recruiting participants, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 3,400 participants, above the 2,673-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (27% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04927429, a study of Cardiovascular Disease, is actively recruiting participants, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

RECRUITING
Registry status
3,400 participants
Enrollment target
2
Study locations

Study Summary

Background: In the U.S., over 6.5 million people have heart failure. Researchers want to develop new testing methods for cardiovascular problems using magnetic resonance imaging (MRI) to improve the clinical diagnosis and management of people with heart failure. Objective: To develop and test new methods for imaging the heart and blood vessels using MRI. Eligibility: People ages 18 years and older who are having an MRI of their heart or blood vessels. Healthy volunteers are also needed. Design: Participants will be screened with a medical history. Participants will have a physical exam and blood tests. They will have an electrocardiogram (ECG) to measure the heart s electrical activity. Then they will have their scheduled MRI scan. The MRI scanner is a large, hollow tube. Participants will lie on a table that moves in and out of the tube. During the MRI, they may have contrast dye injected through an intravenous line inserted into their arm or hand. ECG may be used to monitor their heartbeat or coordinate pictures with their heartbeat. A flexible belt may be used to monitor their breathing. A finger probe may be used to track their heart rate and/or oxygenation level. Their blood pressure may be measured. Pictures may be taken of their blood vessels, heart, and lungs before, during, and after they get medicine to increase blood flow. They may lie flat and pedal a stress bicycle to increase their heart rate. Participation will last for 5 years. During that time, participants may receive a yearly survey about their health. They may be contacted for an optional follow-up MRI within 2 years of their MRI.

Primary Outcome

Clinical performance of pulse sequences measured as the number of subjects with custom and novel pulse sequences that has provided diagnostic quality image

Conditions Studied

Study Locations (2)

District of Columbia

  • Medstar Washington Hospital Center - Washington D.C.

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 3,400 participants
Start Date 2024-04-08
Est. Completion 2031-12-31

What NCT04927429 shows while recruiting

NCT04927429 is an observational study that tracks outcomes without assigning an intervention. Its 3,400 participants enrollment target places it among the larger protocols in the corpus, above the 2,673-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (27% higher).

The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 0 interventions.

NCT04927429 reports a single indexed study location in District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT04927429 about?

NCT04927429 is a clinical study titled "Technical Development of Cardiovascular Magnetic Resonance Imaging". Background: In the U.S., over 6.5 million people have heart failure. Researchers want to develop new testing methods for cardiovascular problems using magnetic resonance imaging (MRI) to improve the clinical diagnosis and management of people with heart failure. Objective: To develop and test new...

What is the current status of trial NCT04927429?

This trial is currently recruiting. The enrollment target is 3,400 participants. The study started on 2024-04-08. Estimated completion is 2031-12-31.

What conditions does trial NCT04927429 study?

This clinical trial studies the following conditions: Cardiovascular Disease.

Who is sponsoring clinical trial NCT04927429?

This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04927429 being conducted?

This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04927429's enrollment target sits among peer trials

3,400 22nd of 137 higher than 116 of 137 other Cardiovascular Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03474029 · 3,400 participants · Phase 2

    Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

  • NCT07142954 · 3,400 participants · Phase 3

    Epidemiology and Biomarker Study in Alzheimer's Disease

  • NCT06880055 · 3,375 participants

    Shield Post-Approval Study Protocol

  • NCT03674307 · 3,306 participants · NA

    Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04927429, the US trial registry maintained by the National Library of Medicine. NCT04927429 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.